Incidence of Hyperpigmentation in Black Patients With Multiple Myeloma Treated With Immunomodulatory Drugs

Completed

Conditions studied: Multiple Myeloma

In brief

The purpose of this study is to measure the incidence of hyperpigmentation in Black participants with multiple myeloma (MM) treated with immunomodulatory drugs (IMiDs) compared with Black participants with MM not treated with IMiDs. The study will use de-identified data from electronic medical records in the Flatiron Health database.

Key facts

Study ID

NCT06160167

Run by

Bristol-Myers Squibb

People needed

4204

Starts

2023-10-01

Expected to finish

2024-08-01

Last updated by the study team

2024-08-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants ≥18 years of age at index date
• Participants with new diagnosis of MM as defined by:
• ICD-9-CM: 203.0x and/or ICD-10-CM: C90.0x or C90 during the study period
• At least two documented clinical visits for MM on different days and occurring on or after January 1, 2011
• Participants who received at least one systemic MM therapy on or after initial MM diagnosis
• Participants who did not receive clinical study drug at any time during the observation period
• Participants with race information

You may not qualify if…

• Exclusion Criteria
• Patients with less than 6 months of medical data during the prior or follow-up period
• Patients in more than one race category (mix race), missing race, unknown race, and "other" race
• Patients diagnosed with the following hematological cancers on or prior to the index date:
• myelodysplastic syndromes (ICD-9: 238.74, 238.75; ICD-10: D46.xx)
• mantle cell lymphoma (ICD-9: 200.4x, ICD-10: C83.1x)
• follicular lymphoma (ICD-9: 202.0x, ICD-10: C82.xx)
• marginal zone lymphoma (ICD-9: 200.3x, ICD-10: C83.4x)
• Patients with evidence of skin hyperpigmentation (ICD-9: 709.00, 709.09; ICD-10: L81.0, L81.1, L81.4, L81.8) on or prior to the index date
• 709.00 Dyschromia, unspecified
• 709.09 Other dyschromia
• L81.0 Post inflammatory hyperpigmentation
• L81.1 Chloasma/melasma
• L81.4 Other melanin hyperpigmentation
• L81.8 Other specified disorders of pigmentation

Where it is running

• Flatiron Health Oncology Database — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.